Your browser version may not work well with NCBI's Web applications. More information
here...
-
- Comment in:
-
Nat Genet. 2006 Jul;38(7):738-40.
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
Weisenberger DJ,
Siegmund KD,
Campan M,
Young J,
Long TI,
Faasse MA,
Kang GH,
Widschwendter M,
Weener D,
Buchanan D,
Koh H,
Simms L,
Barker M,
Leggett B,
Levine J,
Kim M,
French AJ,
Thibodeau SN,
Jass J,
Haile R,
Laird PW.
Department of Surgery, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90089-9176, USA.
Aberrant DNA methylation of CpG islands has been widely observed in human colorectal tumors and is associated with gene silencing when it occurs in promoter areas. A subset of colorectal tumors has an exceptionally high frequency of methylation of some CpG islands, leading to the suggestion of a distinct trait referred to as 'CpG island methylator phenotype', or 'CIMP'. However, the existence of CIMP has been challenged. To resolve this continuing controversy, we conducted a systematic, stepwise screen of 195 CpG island methylation markers using MethyLight technology, involving 295 primary human colorectal tumors and 16,785 separate quantitative analyses. We found that CIMP-positive (CIMP+) tumors convincingly represent a distinct subset, encompassing almost all cases of tumors with BRAF mutation (odds ratio = 203). Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1 . We propose a robust new marker panel to classify CIMP+ tumors.
PMID: 16804544 [PubMed - indexed for MEDLINE]
-
Related Articles